Distribution of human NK cells in reconstituted BRGSF mice with or without Flt3L treatment. (A) Representative flow cytometry immunophenotypic analysis of alive hCD45⁺CD3⁻CD94⁺NKp46⁺ NK cells from liver, spleen, and lung of an Flt3L-treated mouse and a PBS-treated littermate engrafted with the same CD34⁺ HSC donor. (B) Comparison of CD94⁺ cell frequencies within the human CD45⁺ cells (top) and total number of NK cells (bottom) with or without Flt3L treatment in liver, spleen, and lung. (C) Representative flow cytometry plot of CD56 and CD16 expression in liver NKp46⁺CD94⁺ cells as gated in top panels (left) and comparative quantification (right). (D) Expression of NKG2A and NKG2C in liver NKp46⁺CD94⁺ cells (left) and comparative quantification (right). (E) Distribution of activating (CD158i) and inhibitory (CD158a/b) KIR expression in liver, spleen, and lung NK cells of a representative BRGSF mouse treated with Flt3L (left) and comparative quantification of the total KIR-expressing CD94⁺ NK cells with or without Flt3L treatment (right). Each dot represents 1 mouse. Composite data from at least 3 independent experiments are shown. Numbers in plots represent frequencies within gates.